Merck & Company (MRK)

$115.61 -0.30 (-0.26%)
Market Cap 285.83B
Revenue (ttm) 65.01B
Net Income (ttm) 18.25B
EPS (ttm) N/A
PE Ratio 12.89
Forward PE 22.51
Profit Margin 28.08%
Debt to Equity Ratio 0.89
Volume 7,111,000
Avg Vol 12,275,408
Day's Range N/A - N/A
Shares Out 2.47B
Stochastic %K 25%
Beta 0.27
Analysts Strong Sell
Price Target $129.30

Company Profile

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health manageme...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 908 740 4000
Address:
126 East Lincoln Avenue, Rahway, United States
taxplanr
taxplanr Mar. 15 at 3:04 AM
Warnings going out about $MRK rabies pet vaccines being self amplifying and infecting pet owners https://www.instagram.com/reel/DVyZRxFDrFv/?igsh=MTBxYWx1cHQzZWM1dQ==
0 · Reply
QuantInsider
QuantInsider Mar. 14 at 1:16 AM
$MRK saw a big move on the options tape today Around 3:22pm, about 40,000 deep ITM calls traded in seven large blocks for 3/20 expiry That's a ~$102.6M premium, way above existing open interest at the $70 to $90 strikes Price stayed flat, down 0.25% today with no news driving this Feels like complex institutional positioning rather than a clear upside signal Implied vols are high, around 130 to 280% plus, so I'm not jumping in on these calls yet Watching how Monday's open interest shifts and price action around those strikes This one's on the watchlist for now
0 · Reply
clan
clan Mar. 13 at 11:31 PM
$MNKD We know Cipla $CIPLA.NSE has a DPI facility in NY (for Indian Afrezza[?]). Will B.I. build their own DPI facility, or will Mannkind make all the TechnOFEV in Danbury? $MRK $JNJ
0 · Reply
biolover
biolover Mar. 13 at 3:29 PM
$GPCR $VKTX structure has data this month. It is tiny 18 pt arm. But it is a bipolar market and clearly doesn’t understand data at first glance. I had big position in structure and I sold after Lilly attain 1. I don’t beleive in the whole small mole anymore. But all obesity biotech been undervalued vs crazy valuations for others. So people could still do well on structure if data show further wt loss. I would not hold it through the summer as high chance $LLY drug will start showing liver toxicity. It looks peptides may still dominate as injections and orally. Even the incompetent $MRK management could ask their MDs and look at liver enzymes issues.
0 · Reply
taxplanr
taxplanr Mar. 13 at 2:00 PM
There won't be a cancer market left for $BNTX $MRNA $BMY $MRK https://stocktwits.com/news-articles/markets/equity/why-ibrx-rising-today-nk-cell-therapy-update/cZdDfe3RIas
0 · Reply
breakoutstock
breakoutstock Mar. 13 at 7:43 AM
$NKTR folks to give you an idea of the size of the market for REZPEG in 2030 the only Drug that does $30B in sales now is Keytruda. Which accounts for 1/2 of $MRK market cap of $287B Thus in theory if all goes well we could see $130B market cap if it takes over Dupi too.
0 · Reply
Chemaster
Chemaster Mar. 13 at 4:01 AM
$MAIA The 2028 patent cliff poses a $170-350B revenue risk for Big Pharma through 2032, with oncology heavyweights like Merck's Keytruda ($30B annual sales) losing U.S. exclusivity, enabling biosimilars and generics to erode markets—driving urgent M&A (e.g., $173B in at-risk sales by 2032) for innovative assets like MAIA Biotechnology ($MAIA) THIO to fill gaps in immuno-oncology pipelines. THIO's differentiated mechanism, high Phase 3 success probability (96-99% Bayesian), and pan-cancer appeal make it a prime partnership/acquisition target for firms like Merck ($MRK), Bristol Myers Squibb ($BMY), or Pfizer ($PFE) seeking post-cliff growth in a $668B oncology market by 2034. More Information at MAIA Unofficial Reddit Community https://www.reddit.com/r/MAIABiotech/comments/1rscru9/2028_patent_cliff_for_big_pharma/
0 · Reply
truehealthvalue
truehealthvalue Mar. 12 at 8:40 PM
$MRK take a look at $ELTX CEO comment 30’ ago: “Fewer disease progressions and deaths than projected to date have been observed in the ongoing 2:1 randomized Phase 2 AMPLIFY-7P trial” The previous comment by Elicios CEO is key: he is telling you that the results are guaranteed to be good, better than anything currently available. This company could be one of the best investments in the history of biotechnology. It is certainly worth much more than its current valuation. I will Increase my position
0 · Reply
crtlabz
crtlabz Mar. 12 at 7:38 PM
$MRK
0 · Reply
IndyOne
IndyOne Mar. 12 at 5:11 PM
$MRNA Moderna’s mRNA 4157 (V940) combined with Keytruda delivered a durable 49% reduction in recurrence or death for Phase 2b melanoma results. Merck’s Keytruda pulled $31.7B in 2025 revenue. Keytruda’s patent clock is ticking and Merck can extend with mRNA-4157. The 49% RFS benefit holding at 5 years is rare in oncology. Most immunotherapy benefits erode over time. This one didn't. The 62% DMFS reduction is actually the stronger number and it's underreported. Follow the bread crumbs that show news coming on large partnership or buyout $JNJ $MRK $ABBV Will J&J, Merck, or AbbVie make the next move on Moderna's platform? Buy Moderna and hold. Then buy some more.
1 · Reply
Latest News on MRK
Harbor Health Care ETF Q4 2025 Portfolio Review

Mar 11, 2026, 8:18 AM EDT - 3 days ago

Harbor Health Care ETF Q4 2025 Portfolio Review

ABBV ABVX GMAB LLY MASI MEDI RVMD

NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

Mar 4, 2026, 8:00 AM EST - 10 days ago

NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

NTHI

Merck & Co., Inc. (MRK) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 3, 2026, 3:42 PM EST - 11 days ago

Merck & Co., Inc. (MRK) Presents at TD Cowen 46th Annual Health Care Conference Transcript

AI-Powered Tempus Inks New Multi-Year Merck Deal

Mar 3, 2026, 2:33 PM EST - 11 days ago

AI-Powered Tempus Inks New Multi-Year Merck Deal

TEM

KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)

Feb 28, 2026, 10:05 AM EST - 14 days ago

KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)

WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

Feb 28, 2026, 10:00 AM EST - 14 days ago

WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

Merck to lay off around 150 employees at US site amid slump in Gardasil sales

Feb 27, 2026, 12:33 PM EST - 15 days ago

Merck to lay off around 150 employees at US site amid slump in Gardasil sales

KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Feb 27, 2026, 10:15 AM EST - 15 days ago

KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

Feb 27, 2026, 10:00 AM EST - 15 days ago

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer

Feb 26, 2026, 8:00 AM EST - 16 days ago

Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer

Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie

Feb 26, 2026, 7:30 AM EST - 16 days ago

Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie

ABBV

FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis

Feb 25, 2026, 4:30 PM EST - 17 days ago

FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis

Merck's New HIV Drug Shows Promise. Its Chief Medical Officer Explains Why Wall Street Should Care.

Feb 25, 2026, 12:38 PM EST - 17 days ago

Merck's New HIV Drug Shows Promise. Its Chief Medical Officer Explains Why Wall Street Should Care.

Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026

Feb 25, 2026, 12:37 PM EST - 17 days ago

Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026

Merck to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 6:45 AM EST - 18 days ago

Merck to Participate in the TD Cowen 46th Annual Health Care Conference

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

Feb 23, 2026, 3:15 PM EST - 19 days ago

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

MRNA PFE

Merck creates separate oncology arm ahead of Keytruda patent loss

Feb 23, 2026, 9:11 AM EST - 19 days ago

Merck creates separate oncology arm ahead of Keytruda patent loss

Merck Creates Separate Cancer Business. The Stock Is Rising Ahead of Patent Cliff.

Feb 23, 2026, 7:38 AM EST - 19 days ago

Merck Creates Separate Cancer Business. The Stock Is Rising Ahead of Patent Cliff.

Merck Evolves Human Health Operating Structure to Support Portfolio Execution

Feb 23, 2026, 6:45 AM EST - 19 days ago

Merck Evolves Human Health Operating Structure to Support Portfolio Execution

Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports

Feb 23, 2026, 6:22 AM EST - 19 days ago

Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports

Merck is establishing a separate cancer unit. The reorganization of its pharmaceutical business is aimed at bolstering product launches ahead of a key patent loss.

Feb 23, 2026, 6:00 AM EST - 19 days ago

Merck is establishing a separate cancer unit. The reorganization of its pharmaceutical business is aimed at bolstering product launches ahead of a key patent loss.

Harbor Large Cap Value Fund Q4 2025 Portfolio Review

Feb 23, 2026, 5:12 AM EST - 19 days ago

Harbor Large Cap Value Fund Q4 2025 Portfolio Review

AMGN CBSH COF DHR LEN MSFT PH

Merck: Why Investors Should Remain Bullish Despite Patent Risks

Feb 22, 2026, 8:00 AM EST - 20 days ago

Merck: Why Investors Should Remain Bullish Despite Patent Risks

Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons

Feb 19, 2026, 5:15 AM EST - 23 days ago

Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons

Merck Inks AI Drug Discovery Deal With Mayo Clinic To Revolutionize Drug Discovery

Feb 18, 2026, 1:05 PM EST - 24 days ago

Merck Inks AI Drug Discovery Deal With Mayo Clinic To Revolutionize Drug Discovery

Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine

Feb 18, 2026, 6:45 AM EST - 24 days ago

Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine

Impax U.S. Sustainable Economy Fund Q4 2025 Contributors And Detractors

Feb 16, 2026, 10:58 AM EST - 26 days ago

Impax U.S. Sustainable Economy Fund Q4 2025 Contributors And Detractors

AMD GOOG LLY ORCL ZTS

Merck: Keytruda Remains Resilient Despite LOE Risks - Buy Upon Correction

Feb 12, 2026, 9:00 AM EST - 4 weeks ago

Merck: Keytruda Remains Resilient Despite LOE Risks - Buy Upon Correction

These 32 favorite stocks signal the bull market is running on fumes

Feb 12, 2026, 8:05 AM EST - 4 weeks ago

These 32 favorite stocks signal the bull market is running on fumes

AAPL ABT ADBE AMGN AVGO BAC BK

Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium

Feb 12, 2026, 6:45 AM EST - 4 weeks ago

Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium

KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment

Feb 11, 2026, 6:45 AM EST - 4 weeks ago

KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment

Calla Lily Clinical Care and Merck Announce Strategic Collaboration to Advance Intravaginal Drug Delivery Platform

Feb 10, 2026, 4:35 AM EST - 4 weeks ago

Calla Lily Clinical Care and Merck Announce Strategic Collaboration to Advance Intravaginal Drug Delivery Platform

Merck: The Spike Doesn't Make It Overvalued

Feb 9, 2026, 1:32 PM EST - 4 weeks ago

Merck: The Spike Doesn't Make It Overvalued

Merck: A Buy For 2026, But The Clock Is Still Ticking

Feb 9, 2026, 9:55 AM EST - 4 weeks ago

Merck: A Buy For 2026, But The Clock Is Still Ticking

From Bargain To Balancing Act: Merck's Next Test Begins (Rating Downgrade)

Feb 8, 2026, 10:28 PM EST - 4 weeks ago

From Bargain To Balancing Act: Merck's Next Test Begins (Rating Downgrade)

Merck: Pipeline Building Despite The Light FY26 Guide, Major Momentum

Feb 8, 2026, 9:56 PM EST - 4 weeks ago

Merck: Pipeline Building Despite The Light FY26 Guide, Major Momentum

CANCER BREAKTHROUGH: Moderna, Merck report cancer discovery

Feb 4, 2026, 8:15 AM EST - 5 weeks ago

CANCER BREAKTHROUGH: Moderna, Merck report cancer discovery

MRNA

Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript

Feb 3, 2026, 1:30 PM EST - 5 weeks ago

Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript

Pfizer, Merck report Q4 results: Citi's Geoff Meacham on key takeaways

Feb 3, 2026, 11:17 AM EST - 5 weeks ago

Pfizer, Merck report Q4 results: Citi's Geoff Meacham on key takeaways

PFE

Merck's Annual Outlook Falls Short But Keytruda, Animal Health Segments Grow

Feb 3, 2026, 11:06 AM EST - 5 weeks ago

Merck's Annual Outlook Falls Short But Keytruda, Animal Health Segments Grow

Merck tops Q4 earnings expectations but issues weaker 2026 outlook

Feb 3, 2026, 7:14 AM EST - 5 weeks ago

Merck tops Q4 earnings expectations but issues weaker 2026 outlook

Merck's outlook for 2026 comes in lower-than-expected as pipeline faces make-or-break year

Feb 3, 2026, 6:55 AM EST - 5 weeks ago

Merck's outlook for 2026 comes in lower-than-expected as pipeline faces make-or-break year

Merck Earnings Top Estimates. Why the Stock Is Falling.

Feb 3, 2026, 6:48 AM EST - 5 weeks ago

Merck Earnings Top Estimates. Why the Stock Is Falling.

Merck Expects Slower Earnings Growth As It Spends on Acquisitions

Feb 3, 2026, 6:38 AM EST - 5 weeks ago

Merck Expects Slower Earnings Growth As It Spends on Acquisitions

Merck forecasts 2026 sales below estimates on patent losses

Feb 3, 2026, 6:34 AM EST - 5 weeks ago

Merck forecasts 2026 sales below estimates on patent losses

Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms

Feb 3, 2026, 6:31 AM EST - 5 weeks ago

Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms

Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline

Feb 3, 2026, 6:30 AM EST - 5 weeks ago

Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline

5 Stocks That Could Outperform Even in a Pullback

Jan 30, 2026, 1:09 PM EST - 6 weeks ago

5 Stocks That Could Outperform Even in a Pullback

HON MSFT PG

What's Fueling The Rally In Merck Stock?

Jan 28, 2026, 11:10 AM EST - 6 weeks ago

What's Fueling The Rally In Merck Stock?

Merck Announces Second-Quarter 2026 Dividend

Jan 27, 2026, 3:07 PM EST - 6 weeks ago

Merck Announces Second-Quarter 2026 Dividend

taxplanr
taxplanr Mar. 15 at 3:04 AM
Warnings going out about $MRK rabies pet vaccines being self amplifying and infecting pet owners https://www.instagram.com/reel/DVyZRxFDrFv/?igsh=MTBxYWx1cHQzZWM1dQ==
0 · Reply
QuantInsider
QuantInsider Mar. 14 at 1:16 AM
$MRK saw a big move on the options tape today Around 3:22pm, about 40,000 deep ITM calls traded in seven large blocks for 3/20 expiry That's a ~$102.6M premium, way above existing open interest at the $70 to $90 strikes Price stayed flat, down 0.25% today with no news driving this Feels like complex institutional positioning rather than a clear upside signal Implied vols are high, around 130 to 280% plus, so I'm not jumping in on these calls yet Watching how Monday's open interest shifts and price action around those strikes This one's on the watchlist for now
0 · Reply
clan
clan Mar. 13 at 11:31 PM
$MNKD We know Cipla $CIPLA.NSE has a DPI facility in NY (for Indian Afrezza[?]). Will B.I. build their own DPI facility, or will Mannkind make all the TechnOFEV in Danbury? $MRK $JNJ
0 · Reply
biolover
biolover Mar. 13 at 3:29 PM
$GPCR $VKTX structure has data this month. It is tiny 18 pt arm. But it is a bipolar market and clearly doesn’t understand data at first glance. I had big position in structure and I sold after Lilly attain 1. I don’t beleive in the whole small mole anymore. But all obesity biotech been undervalued vs crazy valuations for others. So people could still do well on structure if data show further wt loss. I would not hold it through the summer as high chance $LLY drug will start showing liver toxicity. It looks peptides may still dominate as injections and orally. Even the incompetent $MRK management could ask their MDs and look at liver enzymes issues.
0 · Reply
taxplanr
taxplanr Mar. 13 at 2:00 PM
There won't be a cancer market left for $BNTX $MRNA $BMY $MRK https://stocktwits.com/news-articles/markets/equity/why-ibrx-rising-today-nk-cell-therapy-update/cZdDfe3RIas
0 · Reply
breakoutstock
breakoutstock Mar. 13 at 7:43 AM
$NKTR folks to give you an idea of the size of the market for REZPEG in 2030 the only Drug that does $30B in sales now is Keytruda. Which accounts for 1/2 of $MRK market cap of $287B Thus in theory if all goes well we could see $130B market cap if it takes over Dupi too.
0 · Reply
Chemaster
Chemaster Mar. 13 at 4:01 AM
$MAIA The 2028 patent cliff poses a $170-350B revenue risk for Big Pharma through 2032, with oncology heavyweights like Merck's Keytruda ($30B annual sales) losing U.S. exclusivity, enabling biosimilars and generics to erode markets—driving urgent M&A (e.g., $173B in at-risk sales by 2032) for innovative assets like MAIA Biotechnology ($MAIA) THIO to fill gaps in immuno-oncology pipelines. THIO's differentiated mechanism, high Phase 3 success probability (96-99% Bayesian), and pan-cancer appeal make it a prime partnership/acquisition target for firms like Merck ($MRK), Bristol Myers Squibb ($BMY), or Pfizer ($PFE) seeking post-cliff growth in a $668B oncology market by 2034. More Information at MAIA Unofficial Reddit Community https://www.reddit.com/r/MAIABiotech/comments/1rscru9/2028_patent_cliff_for_big_pharma/
0 · Reply
truehealthvalue
truehealthvalue Mar. 12 at 8:40 PM
$MRK take a look at $ELTX CEO comment 30’ ago: “Fewer disease progressions and deaths than projected to date have been observed in the ongoing 2:1 randomized Phase 2 AMPLIFY-7P trial” The previous comment by Elicios CEO is key: he is telling you that the results are guaranteed to be good, better than anything currently available. This company could be one of the best investments in the history of biotechnology. It is certainly worth much more than its current valuation. I will Increase my position
0 · Reply
crtlabz
crtlabz Mar. 12 at 7:38 PM
$MRK
0 · Reply
IndyOne
IndyOne Mar. 12 at 5:11 PM
$MRNA Moderna’s mRNA 4157 (V940) combined with Keytruda delivered a durable 49% reduction in recurrence or death for Phase 2b melanoma results. Merck’s Keytruda pulled $31.7B in 2025 revenue. Keytruda’s patent clock is ticking and Merck can extend with mRNA-4157. The 49% RFS benefit holding at 5 years is rare in oncology. Most immunotherapy benefits erode over time. This one didn't. The 62% DMFS reduction is actually the stronger number and it's underreported. Follow the bread crumbs that show news coming on large partnership or buyout $JNJ $MRK $ABBV Will J&J, Merck, or AbbVie make the next move on Moderna's platform? Buy Moderna and hold. Then buy some more.
1 · Reply
Davidendz
Davidendz Mar. 12 at 4:50 PM
Immuno oncology momentum is real. $BNTX expanding oncology. $MRK pushing deeper into bladder with checkpoint combos. Sector trend is clear: vaccines + checkpoint inhibitors = better durability. $BIOV.CSE $BVAXF advancing MVP S with positive multi cancer data, including 24% ORR in ovarian. Platform leverage in a combo driven market.
0 · Reply
erevnon
erevnon Mar. 12 at 4:19 PM
Wells Fargo maintains Merck & Co $MRK at Overweight and raises the price target from $135 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Quantumup
Quantumup Mar. 12 at 2:55 PM
Cantor reiterated $CMPX at an Overweight rating, and said: In April, we expect the long-awaited PFS/OS readout from the Phase 2/3 COMPANION-002 trial of tovecimig (DLL4 x VEGF-A) in second-line biliary tract cancer (BTC). $AZN $MRK PFE RLAY Cantor added—This represents a high-stakes readout for Compass and one we view with cautious optimism. In this note, we walk through trial background, expectations for PFS and OS, potential stock scenarios, and key risks. We believe the trial is highly likely to achieve statistical significance on PFS, broadly in line with investor expectations. The core debate centers on overall survival (OS) and whether the study will clear the statistical threshold on this secondary endpoint. Given that ~80% OS events were triggered in 1Q26, in-line with our assumptions in our initiation report, we maintain our ~50% probability of success for OS.
0 · Reply
taxplanr
taxplanr Mar. 12 at 2:54 PM
Did you know the CIA has known since 1951 that dewormers fight cancer? $BNTX $MRNA $BMY $MRK https://www.msn.com/en-us/health/other/cia-faces-furious-backlash-after-hidden-document-hints-at-possible-cancer-cure/ar-AA1XQBYt
0 · Reply
4RUNNA
4RUNNA Mar. 12 at 7:47 AM
$JNJ VS $MRK VS $IBRX
0 · Reply
Kanate123
Kanate123 Mar. 12 at 3:39 AM
$MRK everyone needs cdxs codexis . This company in my opinion has to get auired by one of the big pharmas. It makes the drugs and merk needs the platform exclusively. codexis symbol cdxs can go t he moon
0 · Reply
TechTraderGrok
TechTraderGrok Mar. 11 at 7:56 PM
Bought $MRK at $116.18. From Grok: "Recommend LONG on MRK as new AI-oncology partnership with Tempus provides strong bullish catalyst differing from prior weak guidance exit, with oversold Stoch at 12.48, price at BB lower 115.99 near support, and MACD histogram improving from -0.48 to 0.60 despite still bearish, justifying quick re-entry at better 115.99 vs 116.07 exit as breakdown eases in uptrend pullback." https://www.techtrader.ai/grokwall/?post=16879&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
taxplanr
taxplanr Mar. 11 at 2:39 PM
Here is what real Cancer cure results and manufacturing look like $BNTX $MRNA $BMY $MRK
0 · Reply
PMMstocks
PMMstocks Mar. 11 at 9:00 AM
$ELTX $RVMD $MRK https://www.investing.com/news/analyst-ratings/rodman--renshaw-initiates-elicio-therapeutics-stock-with-buy-rating-93CH-4550688
0 · Reply
clan
clan Mar. 11 at 2:20 AM
$MNKD Trolls r idiots. 🤑CEO, Lasagna, puts his own pocket change where his mouth is! Buys 100,000 shares on open market! For the good of all Mannkind. $SPY $MRK $IBB
0 · Reply
showtime1
showtime1 Mar. 10 at 10:04 PM
$IMMP $MRK Buy them baby!! Lets go..still waiting lol..
0 · Reply
taxplanr
taxplanr Mar. 10 at 2:08 PM
NIH launches studies of Ivermectin to treat Cancer $BNTX $MRNA $BMY $MRK https://kffhealthnews.org/news/article/ivermectin-cancer-treatment-nih-study-dewormer-offlabel-drug/
0 · Reply